Results 141 to 150 of about 4,142 (167)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Clinical, Cosmetic and Investigational Dermatology, 2022
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini   +2 more
exaly  

Real World Practice Indirect Comparison Between Guselkumab and Risankizumab: Results From an Italian Retrospective Study

Dermatologic Therapy, 2022
Angelo Ruggiero, Matteo Megna, Eleonora Cinelli   +2 more
exaly  

Guselkumab in Biologic-Naive Patients With Active Psoriatic Arthritis (DISCOVER-2): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial

Lancet, The, 2020
Elizabeth Ohneck, Alice B Gottlieb, Proton Rahman   +2 more
exaly  

Treatment Response of Patients With Erythrodermic Psoriasis After Switching to Guselkumab

Dermatology and Therapy, 2021
Cheng-Ying Chiang, Tsen-Fang Tsai
exaly  

Guselkumab (Tremfya) for Ulcerative Colitis

The Medical Letter on Drugs and Therapeutics
The interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of
openaire   +2 more sources

Guselkumab: The First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults

Expert Review of Clinical Immunology, 2021
Wolf-Henning Boehncke, Michael John Nissen, Nicolò C Brembilla   +2 more
exaly  

Etanercept/guselkumab

Reactions Weekly, 2023
openaire   +1 more source

Efficacy and Safety of Guselkumab in Patients With Active Psoriatic Arthritis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Lancet, The, 2018
Juan J Gómez-Reino, Melinda Gooderham, Kim A. Papp   +2 more
exaly  

Guselkumab Versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results From a Phase 3, Randomised Controlled Trial

Lancet, The, 2019
Kristian Reich, Bruce Randazzo, Andrew Blauvelt   +2 more
exaly  

Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared With Adalimumab for the Treatment of Patients With Moderate to Severe Psoriasis With Randomized Withdrawal and Retreatment: Results From the Phase III, Double-Blind, Placebo- and Active Comparator–Controlled VOYAGE 2 Trial

Journal of the American Academy of Dermatology, 2017
Kristian Reich, Peter Foley, Michael Song   +2 more
exaly